Literature DB >> 21785318

Association of osteonecrosis and osteoporosis in HIV-1-infected patients.

W Jeffrey Fessel1, Quyen Chau, Davis Leong.   

Abstract

BACKGROUND: We questioned whether heightened impairment of regenerative capacity of osteoblasts might account for the excess of osteonecrosis and osteoporosis seen in HIV-infected patients. Were that the case, patients with osteonecrosis would have more osteoporosis than the patients without osteonecrosis.
METHODS: Eleven thousand, five hundred and six patients with HIV infection were studied for the presence of osteonecrosis and osteoporosis and for confounding factors.
RESULTS: Depending upon whether dual-energy X-ray absorptiometry (DEXA) was before or after the diagnosis of osteonecrosis, osteoporosis was between 6.3 and 18 times more frequent in those with than in those without osteonecrosis. Those who received DEXA were similar to those who did not in median CD4 level at the time of DEXA or at a comparable time after their first recorded CD4 cell count in our system; in nadir CD4 level; and in use and amount of corticosteroids. Those with osteonecrosis and osteoporosis did not use more corticosteroids than those with osteoporosis without osteonecrosis. Alcohol abuse had not been diagnosed more often before the occurrence of osteonecrosis than in those without osteonecrosis. Tenofovir was not more used by those with than by those without osteoporosis.
CONCLUSION: Osteonecrosis and osteoporosis in HIV-infected patients were concurrent more often than expected.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785318     DOI: 10.1097/QAD.0b013e32834af637

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.

Authors:  Kazuyo Takeda; Rewati Adhikari; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

2.  Prevalence and predictors of low bone mineral density in treatment-naive HIV-infected patients and its correlation with CD4 cell counts.

Authors:  Pulin Kumar Gupta; Sanchit Singh; Subodh Kumar Mahto; Ankita Sheoran; Umesh Chand Garga; Ashok Kumar Lal; Piyush Jain; Sujata Elizabeth Mathews
Journal:  Tzu Chi Med J       Date:  2020-04-10

3.  Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.

Authors:  Wei Lin; Xing-Fu Li; Dong-Cheng Ren; Meng Song; Li Duan; Jin-Zhu Liu; Zi-Rui Zhan
Journal:  Mol Med       Date:  2021-02-26       Impact factor: 6.354

4.  Relation between the development of osteoporosis and osteonecrosis following glucocorticoid in a rabbit model.

Authors:  Tao Lin; Junbin Liu; Shuhua Yang; Xianzhe Liu; Xiaobo Feng; Dehao Fu
Journal:  Indian J Orthop       Date:  2016 Jul-Aug       Impact factor: 1.251

5.  Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study.

Authors:  Cornelia Bayard; Bruno Ledergerber; Markus Flepp; Thanh Lecompte; Estelle Moulin; Matthias Hoffmann; Rainer Weber; Cornelia Staehelin; Caroline Di Benedetto; Christoph A Fux; Philip E Tarr; Barbara Hasse
Journal:  Open Forum Infect Dis       Date:  2017-08-22       Impact factor: 3.835

6.  Osteonecrosis of the femoral head in people living with HIV: anatomopathological description and p24 antigen test.

Authors:  Ana Lucia L Munhoz Lima; Priscila Rosalba Oliveira; Vladimir C Carvalho; Alexandre Leme Godoy-Santos; Leandro Ejnisman; Claudia R Oliveira; David E Uip; Maria Irma S Duarte
Journal:  HIV AIDS (Auckl)       Date:  2018-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.